Back to Search
Start Over
Adults with Severe or Moderately Severe Hemophilia B Receiving Etranacogene Dezaparvovec in the HOPE-B Phase 3 Clinical Trial Continue to Experience a Stable Increase in Mean Factor IX Activity Levels and Durable Hemostatic Protection after 24 Months’ Follow-up
- Source :
- Blood. 140:4910-4912
- Publication Year :
- 2022
- Publisher :
- American Society of Hematology, 2022.
- Subjects :
- Immunology
Cell Biology
Hematology
Biochemistry
Subjects
Details
- ISSN :
- 15280020 and 00064971
- Volume :
- 140
- Database :
- OpenAIRE
- Journal :
- Blood
- Accession number :
- edsair.doi...........4b86c7f230f3b01e0b00251a5a245fbc